MG
OMIC

Michael Gelband’s Singular Genomics Systems, Inc. Common Stock OMIC Stock Holding History

Michael Gelband’s Portfolio OMIC Stock Details OMIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-530
Closed -$437K – 2778
2021
Q2 		$437K Buy
+530
New +$411K ﹤0.01% 1532

Other funds holding OMIC

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Coatue Management
Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NIP
Nicholas Investment Partners Rancho Santa Fe, California $1.78B AUM 114.03% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

Michael Gelband's OMIC Position: Q3 2021 in Review

Michael Gelband sold out of Singular Genomics Systems, Inc. Common Stock (OMIC) in Q3 2021, closing a stake of 530 shares — an estimated $437K sold.

Michael Gelband first reported a position in OMIC in Q2 2021 and held it in 1 quarter. The position peaked at $437K in Q2 2021. 52 funds tracked by Wall St. Rank hold OMIC as of Q3 2021.

  • Michael Gelband reported no remaining Singular Genomics Systems, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • Michael Gelband sold 530 Singular Genomics Systems, Inc. Common Stock shares in Q3 2021, an estimated $437K.
  • Michael Gelband first reported a position in Singular Genomics Systems, Inc. Common Stock in Q2 2021 and held it in 1 quarter.
  • Michael Gelband's Singular Genomics Systems, Inc. Common Stock position peaked at $437K in Q2 2021.
  • 52 funds tracked by Wall St. Rank held Singular Genomics Systems, Inc. Common Stock as of Q3 2021.

Based on ExodusPoint Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.